Drug intelligence / Profile preview

ziconotide

Development stage
Approved
Lead developer
Neurex
Modality
Peptides
Administration
Intrathecal
01

Overview

Ziconotide is a synthetic peptide analgesic derived from the venom of the marine cone snail Conus magus. It is used for the management of severe chronic pain in patients who are refractory to other treatments, such as intrathecal morphine or systemic analgesics. Ziconotide acts as a potent and selective blocker of N-type voltage-gated calcium channels (specifically those containing the α1B subunit, also known as CaV2.2) located primarily in the dorsal horn of the spinal cord. By inhibiting these channels, ziconotide prevents neurotransmitter release from primary nociceptive afferents and blocks pain signal transmission to the brain. The drug is administered exclusively via intrathecal infusion due to its peptide nature and narrow therapeutic window. Ziconotide does not cause tolerance with chronic use but can be associated with significant neuropsychiatric side effects and must be dosed carefully under medical supervision[3][5][6][8].

Brand names
Prialt
Other names
omega-conotoxin MVIIAω-conotoxin MVIIA
02

Targets

CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)

Beyond the preview

Go deeper on ziconotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ziconotide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call